P13 ‘Microneedle’ A new horizon of intradermal therapeutics

Abstract

Abstract Microneedle array patch (MAP) is a patch of sharp but painless microstructure needles ranging from only a few microneedles to several hundred, attached to an adhesive patch. The arrays penetrate the outer layer of the skin on application and then are given time to dissolve to deliver a local dose of medication intradermally (https://www.youtube.com/watch?v=F6jPA9liUMc ). MAP enable alternative and easier delivery scenarios for physicians as they require less training to apply and not as hazardous as traditional needles. MAP also improve adherence to drug regimens as it makes the administration of drugs to patients safer and less painful. Additionally, microneedles offer suitability for self-administration, no biohazardous sharps waste, and no risk of needle-stick injuries. The work that supported the preliminary research/development have been patented/published (Patent WO 2020/250210). The key opinion leaders KOLs and industry stakeholder feedback confirmed an unmet market need for the MN technology, particularly in support of many topical applications. The in-vivo data showed that the MAP delivers a superior localized drug dose compared current standard of care, which should translate to a reduced treatment-time. Also, the comparative plasma bioavailability of the MAP translates to less side effects. It was also observed that after one week, there was no sign of inflammation or irritation at the site of application. We are seeking potential clinical partners for whom collaboration and MAP technology is advantageous. Such collaboration would ensure rapid product development and industrial production to allow clinical assessment.